NNVC

Business Context and Reporting Period

NanoViricides, Inc. (NNVC) is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral nanomedicines. The company operates a cGMP-compliant manufacturing facility in Shelton, Connecticut. This Form 10-Q covers the quarterly period ended December 31, 2024, and the six months ended on that date. The company has no commercial revenue and relies on equity financing and potential grants to fund operations.

Key Financial Metrics

Debt and Liquidity: The company has an accumulated deficit of approximately $144.5 million. It maintains a $3 million line of credit with a related party (Dr. Anil Diwan), which has not been drawn upon as of December 31, 2024. Current liabilities include approximately $867,000 in accounts payable to related parties.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased to $5.23 million for the six months ended December 31, 2024, compared to $4.22 million in the prior year period.
  • Research and Development (R&D): Increased slightly to $3.09 million (from $3.04 million) due to higher outside lab fees.
  • General and Administrative (G&A): Increased significantly to $2.14 million (from $1.18 million), primarily driven by increased professional fees associated with investor outreach activities.
• Interest Income: Decreased to $72,732 (from $182,472) due to lower interest-bearing balances and lower interest rates.
• Interest Expense: Decreased to $149 (from $49,808) as interest on a related-party milestone note was cancelled in the prior year.
• Financing Activities: The company raised approximately $3.99 million in net proceeds from the sale of common stock via its At-The-Market (ATM) program during the six-month period, compared to no equity financing in the prior year period.

Outlook, Risks, and Management Commentary

Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. With approximately $4.0 million in cash and a burn rate of roughly $4.8 million over six months, existing resources (including the undrawn line of credit) are deemed insufficient to fund planned operations for the next 12 months. The company is actively seeking additional equity financing, debt, or non-dilutive grants.

Development Pipeline:

• NV-387: The lead drug candidate has successfully completed a Phase I safety and tolerability trial with no adverse events. The company is preparing for Phase II clinical trials targeting MPox (in Central Africa), pediatric RSV, and potentially H5N1 Bird Flu.
• NV-HHV-1: A drug candidate for Shingles and Herpes is in advanced pre-clinical stages, with plans to move to clinical trials after NV-387 Phase II initiation.

Risks and Contingencies:

• Capital Requirements: Failure to secure additional funding could force the company to delay or curtail clinical trials.
• Related Party Dependence: The company relies on TheraCour Pharma, Inc. (owned by the CEO) for technology licensing and manufacturing support. Significant related-party payables exist.
• Regulatory Uncertainty: No assurance exists that Phase II trials will succeed or that regulatory approval will be granted.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.96 million cash balance against the current burn rate and the timeline for the next financing round.
• Related Party Transactions: Review the $866,783 in accounts payable to related parties and the terms of the $3 million line of credit to assess potential conflicts or liquidity constraints.
• Phase II Progress: Monitor the submission and acceptance of the Clinical Trial Application (CTA) for the MPox Phase II trial and the engagement of the CRO.
• ATM Utilization: Track the remaining capacity under the $50 million ATM agreement and the pricing of recent share sales to assess dilution risks.
• Intellectual Property: Confirm the status of the exclusive licenses with TheraCour and the validity of the underlying patents.